Navigation Links
Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
Date:1/6/2011

DANBURY, Conn., Jan. 6, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the 29th Annual JPMorgan Healthcare Conference on Thursday, January 13, 2011 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The update will include information about the development of new follow-on formulations of its lead product, Linjeta™, including milestones and timelines.

The JPMorgan Healthcare Conference will be held January 9-13, 2011, at the Westin St. Francis Hotel in San Francisco, California.

Interested parties may access the presentation in the investor relations section of Biodel's website at www.biodel.com which will link to a live webcast to be archived for 14 days.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

CONTACT: Seth Lewis, +1-646-378-2952

News Provided by Acquire Media


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. InterMune to Present at Canaccord Adams Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
6. Bionovo to Present at Canaccord Adams Global Growth Conference
7. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):